A novel platinum-based chemotherapeutic inducing immunogenic cell death

Kepp, Oliver

doi:10.1080/2162402x.2020.1729022

Cited by 10 publications

(8 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This new platinum-based complex led to platinum-induced ICD and possessed the characteristics of diclofenac, with the presence of diclofenac increasing the selectivity and cytotoxicity of platinum on six human cancer cell line (cervical carcinoma HeLa, breast adenocarcinomas MDA-MB-231 and MCF-7, colon carcinoma HCT-116, ovarian carcinoma A2780 and A2780cisR), and one non-cancerous fibroblast cell line (MRC-5) ( Kostrhunova et al, 2023 ). R,R-1,2 cyclohexane diaminepyrophosphato-platinum (II) (PT-112) is another promising platinum-based compound ( Kepp and Kroemer, 2020 ). Based on platinum (II) and pyrophosphate, PT-112 confers strong and long-lasting protective effects on murine colorectal carcinoma CT26 and MC38 cells making it a suitable inducer ( Yamazaki et al, 2020 ).…”

Section: Icd Inducers and Molecular Mechanismmentioning

confidence: 99%

“…A2780cisR), and one non-cancerous fibroblast cell line (MRC-5) (Kostrhunova et al, 2023). R,R-1,2 cyclohexane diaminepyrophosphato-platinum (II) (PT-112) is another promising platinum-based compound (Kepp and Kroemer, 2020). Based on platinum (II) and pyrophosphate, PT-112 confers strong and long-lasting protective effects on murine colorectal carcinoma CT26 and MC38 cells making it a suitable inducer (Yamazaki et al, 2020).…”

Section: Chemotherapy Combination Complexmentioning

confidence: 99%

See 1 more Smart Citation

Clinical application of immunogenic cell death inducers in cancer immunotherapy: turning cold tumors hot

Han,

Tian,

Zhai

et al. 2024

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Immunotherapy has emerged as a promising cancer treatment option in recent years. In immune “hot” tumors, characterized by abundant immune cell infiltration, immunotherapy can improve patients’ prognosis by activating the function of immune cells. By contrast, immune “cold” tumors are often less sensitive to immunotherapy owing to low immunogenicity of tumor cells, an immune inhibitory tumor microenvironment, and a series of immune-escape mechanisms. Immunogenic cell death (ICD) is a promising cellular process to facilitate the transformation of immune “cold” tumors to immune “hot” tumors by eliciting innate and adaptive immune responses through the release of (or exposure to) damage-related molecular patterns. Accumulating evidence suggests that various traditional therapies can induce ICD, including chemotherapy, targeted therapy, radiotherapy, and photodynamic therapy. In this review, we summarize the biological mechanisms and hallmarks of ICD and introduce some newly discovered and technologically innovative inducers that activate the immune system at the molecular level. Furthermore, we also discuss the clinical applications of combing ICD inducers with cancer immunotherapy. This review will provide valuable insights into the future development of ICD-related combination therapeutics and potential management for “cold” tumors.

show abstract

Section: Icd Inducers and Molecular Mechanismmentioning

confidence: 99%

Section: Chemotherapy Combination Complexmentioning

confidence: 99%

Clinical application of immunogenic cell death inducers in cancer immunotherapy: turning cold tumors hot

Han,

Tian,

Zhai

et al. 2024

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

show abstract

“…However, certain chemotherapeutic drugs, particularly anthracyclines and oxaliplatin, can trigger immunogenic cell death characterized by the translocation of calreticulin (CRT) from the endoplasmic reticulum to the cell surface. 15,16 CRT exposed on the cell surface acts as an “eat-me” signal that facilitates phagocytic clearance of tumor cells by binding to CD91 on phagocytic cells such as macrophages and dendritic cells (DC). 13 These phagocytes can also present internalized tumor antigen peptides to T cells, thereby initiating antigen-specific immune responses.…”

Section: Introductionmentioning

confidence: 99%

Improving nanochemoimmunotherapy efficacy by boosting “eat-me” signaling and downregulating “don't-eat-me” signaling with Ganoderma lucidum polysaccharide-based drug delivery

Pang,

Wei,

Zhao

et al. 2023

J. Mater. Chem. B

View full text Add to dashboard Cite

show abstract

“…Consequently, it induces immunogenic cell death (ICD) within the tumor and initiates anti-tumor T-cell immune responses. [12][13][14] Based on the ASTRUM-007 study, Serplulimab as a PD-1/PD-L1 inhibitor, used in combination with CDDP for adjuvant and advanced first-line treatment of esophageal cancer. [15] Compared with single immunotherapy, the efficacy has been significantly improved.…”

Section: Introductionmentioning

confidence: 99%

Tackling Esophageal Squamous Cell Carcinoma with ITFn‐Pt(IV): A Novel Fusion of PD‐L1 Blockade, Chemotherapy, and T‐cell Activation

Xin,

Wang,

Wang

et al. 2023

Adv Healthcare Materials

View full text Add to dashboard Cite

PD‐1/PD‐L1 blockade immunotherapy has gained approval for the treatment of a diverse range of tumors; however, its efficacy is constrained by the insufficient infiltration of T lymphocytes into the tumor microenvironment, resulting in suboptimal patient responses. Here, a pioneering immunotherapy ferritin nanodrug delivery system denoted as ITFn‐Pt(IV) is introduced. This system orchestrates a synergistic fusion of PD‐L1 blockade, chemotherapy, and T‐cell activation, aiming to augment the efficacy of tumor immunotherapy. Leveraging genetic engineering approach and temperature‐regulated channel‐based drug loading techniques, the architecture of this intelligent responsive system is refined. It is adept at facilitating the precise release of T‐cell activating peptide Tα1 in the tumor milieu, leading to an elevation in T‐cell proliferation and activation. The integration of PD‐L1 nanobody KN035 ensures targeted engagement with tumor cells and mediates the intracellular delivery of the encapsulated Pt(IV) drugs, culminating in immunogenic cell death and the subsequent dendritic cell maturation. Employing esophageal squamous cell carcinoma (ESCC) as tumor model, the potent antitumor efficacy of ITFn‐Pt(IV) is elucidated, underscored by augmented T‐cell infiltration devoid of systemic adverse effects. These findings accentuate the potential of ITFn‐Pt(IV) for ESCC treatment and its applicability to other malignancies resistant to established PD‐1/PD‐L1 blockade therapies.

show abstract

A novel platinum-based chemotherapeutic inducing immunogenic cell death

Cited by 10 publications

References 12 publications

Clinical application of immunogenic cell death inducers in cancer immunotherapy: turning cold tumors hot

Clinical application of immunogenic cell death inducers in cancer immunotherapy: turning cold tumors hot

Improving nanochemoimmunotherapy efficacy by boosting “eat-me” signaling and downregulating “don't-eat-me” signaling with Ganoderma lucidum polysaccharide-based drug delivery

Tackling Esophageal Squamous Cell Carcinoma with ITFn‐Pt(IV): A Novel Fusion of PD‐L1 Blockade, Chemotherapy, and T‐cell Activation

Contact Info

Product

Resources

About